PMID- 28618412
OWN - NLM
STAT- MEDLINE
DCOM- 20180813
LR  - 20180813
IS  - 1421-9751 (Electronic)
IS  - 0008-6312 (Linking)
VI  - 138
IP  - 2
DP  - 2017
TI  - Failed Downregulation of Circulating MicroRNA-155 in the Early Phase after ST 
      Elevation Myocardial Infarction Is Associated with Adverse Left Ventricular 
      Remodeling.
PG  - 91-96
LID - 10.1159/000477235 [doi]
AB  - BACKGROUND: MicroRNA are noncoding RNA that have a significant role in both 
      inflammatory and cardiovascular diseases. AIMS: We aimed to assess whether the 
      inflammation-related microRNA-155 is associated with the development of adverse 
      left ventricular (LV) remodeling following ST elevation myocardial infarction 
      (STEMI). METHODS: Peripheral blood samples were collected in the inflammatory 
      (day 2), proliferative (day 5), and maturation phases (6 months) after STEMI (n = 
      20). Granulocytes, monocytes, and lymphocytes were enumerated with flow 
      cytometry. The changes in LV volumes were assessed with 3-D echocardiography on 
      day 1 and after 6 months. Adverse remodeling was defined as a >20% increase in 
      end-diastolic volume. Healthy subjects were recruited as controls. RESULTS: 
      MicroRNA-155 measured on day 5 correlated positively with the relative change in 
      end-diastolic volume (rho = 0.490, p = 0.028). MicroRNA-155 (day 5) was 
      significantly higher in patients with compared to patients without adverse LV 
      remodeling. The expression level was similar in healthy subjects (n = 8) and in 
      patients with LV remodeling. There was a positive correlation between 
      microRNA-155 and the amount of monocytes (day 5, rho = 0.463, p = 0.046). 
      CONCLUSION: Impaired downregulation of microRNA-155 during the second phase of 
      the post- STEMI inflammatory response is a determinant of the development of 
      adverse LV remodeling.
CI  - (c) 2017 S. Karger AG, Basel.
FAU - Latet, Sam C
AU  - Latet SC
AD  - Cardiovascular Diseases, University of Antwerp, Antwerp, Belgium.
FAU - Van Herck, Paul L
AU  - Van Herck PL
FAU - Claeys, Marc J
AU  - Claeys MJ
FAU - Van Craenenbroeck, Amaryllis H
AU  - Van Craenenbroeck AH
FAU - Haine, Steven E
AU  - Haine SE
FAU - Vandendriessche, Tom R
AU  - Vandendriessche TR
FAU - Van Hoof, Viviane O
AU  - Van Hoof VO
FAU - Fransen, Erik
AU  - Fransen E
FAU - De Winter, Benedicte Y
AU  - De Winter BY
FAU - Van Craenenbroeck, Emeline M
AU  - Van Craenenbroeck EM
FAU - Heidbuchel, Hein
AU  - Heidbuchel H
FAU - Vrints, Christiaan J
AU  - Vrints CJ
FAU - Hoymans, Vicky Y
AU  - Hoymans VY
LA  - eng
PT  - Journal Article
DEP - 20170616
PL  - Switzerland
TA  - Cardiology
JT  - Cardiology
JID - 1266406
RN  - 0 (MIRN155 microRNA, human)
RN  - 0 (MicroRNAs)
SB  - IM
CIN - Cardiology. 2017;138(2):89-90. PMID: 28618408
CIN - Cardiology. 2017;138(2):87-88. PMID: 28618414
MH  - Aged
MH  - Case-Control Studies
MH  - Echocardiography, Three-Dimensional
MH  - Female
MH  - Gene Expression Regulation
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - MicroRNAs/*blood/genetics
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention
MH  - ST Elevation Myocardial Infarction/*blood/*physiopathology/surgery
MH  - Treatment Outcome
MH  - Ventricular Function, Left
MH  - *Ventricular Remodeling
OTO - NOTNLM
OT  - MicroRNA-155
OT  - Myocardial infarction
OT  - Ventricular remodeling
EDAT- 2017/06/16 06:00
MHDA- 2018/08/14 06:00
CRDT- 2017/06/16 06:00
PHST- 2017/01/06 00:00 [received]
PHST- 2017/04/26 00:00 [accepted]
PHST- 2017/06/16 06:00 [pubmed]
PHST- 2018/08/14 06:00 [medline]
PHST- 2017/06/16 06:00 [entrez]
AID - 000477235 [pii]
AID - 10.1159/000477235 [doi]
PST - ppublish
SO  - Cardiology. 2017;138(2):91-96. doi: 10.1159/000477235. Epub 2017 Jun 16.